Genomic Health Inc. (GHDX)

32.26
0.06 0.19
NASDAQ : Health Technology
Prev Close 32.20
Open 32.05
Day Low/High 31.82 / 32.84
52 Wk Low/High 26.54 / 37.50
Volume 58.91K
Avg Volume 188.50K
Exchange NASDAQ
Shares Outstanding 35.32M
Market Cap 1.18B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $33.11/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX® AR-V7 Nucleus Detect™ Test To Predict Treatment Response In Metastatic Disease

Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX® AR-V7 Nucleus Detect™ Test To Predict Treatment Response In Metastatic Disease

New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer

Genomic Health Reaches Analyst Target Price

Genomic Health Reaches Analyst Target Price

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $32.28, changing hands for $32.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Oncotype DX® Genomic Prostate Score™ Test Increases Use Of Active Surveillance By 30 Percent In Low-risk Patients, Resulting In Greater Adherence To Guideline-based Care

Oncotype DX® Genomic Prostate Score™ Test Increases Use Of Active Surveillance By 30 Percent In Low-risk Patients, Resulting In Greater Adherence To Guideline-based Care

Unprecedented Study of Nearly 10,000 Patient Medical Records from Large Private U.S. Health Insurer Published in Reviews in Urology

Oversold Conditions For Genomic Health (GHDX)

Oversold Conditions For Genomic Health (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Presents New Data Demonstrating Value Of Oncotype DX® To Optimize Breast Cancer Outcomes And Reduce Treatment Burden Throughout Disease Continuum

Genomic Health Presents New Data Demonstrating Value Of Oncotype DX® To Optimize Breast Cancer Outcomes And Reduce Treatment Burden Throughout Disease Continuum

New Data Supports Expanded Use of Oncotype DX Breast Recurrence Score® Test for Predicting Treatment Benefit in Neoadjuvant Setting

Genomic Health Announces Research Collaboration With Janssen Pharmaceuticals To Evaluate The Oncotype DX® Genomic Prostate Score™ Test For Potential Drug Development

Genomic Health Announces Research Collaboration With Janssen Pharmaceuticals To Evaluate The Oncotype DX® Genomic Prostate Score™ Test For Potential Drug Development

Additionally, Genomic Health Makes a $4M Equity Investment in Biocartis, Furthering Collaboration to Develop an IVD version of the Oncotype DX Breast Recurrence Score® Test

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

Global Licensing Agreement Provides Genomic Health with Exclusive Rights to Cleveland Diagnostics' Proprietary IsoPSA™ Technology

Relative Strength Alert For Genomic Health

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.90, changing hands for $32.15/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Commit To Buy Genomic Health At $22.50, Earn 10.9% Annualized Using Options

Investors considering a purchase of Genomic Health Inc stock, but cautious about paying the going market price of $26.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $22.50 strike, which has a bid at the time of this writing of $1.25.

Genomic Health (GHDX): Today's Weak On High Volume Stock

Genomic Health (GHDX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Genomic Health (GHDX) Strong On High Relative Volume Today

Genomic Health (GHDX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Genomic Health (GHDX) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Today's Weak On High Volume Stock: Genomic Health (GHDX)

Trade-Ideas LLC identified Genomic Health (GHDX) as a weak on high relative volume candidate

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Commit To Purchase Genomic Health At $17.50, Earn 6.4% Annualized Using Options

Investors eyeing a purchase of Genomic Health Inc shares, but tentative about paying the going market price of $23.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $17.50 strike, which has a bid at the time of this writing of 55 cents.

TheStreet Quant Rating: C (Hold)